Acrónimos

Acrónimo Significado
AAS Ácido Acetil Salicílico
AACE/ACE American Association of Clinical Endocrinologists/American College of Endocrinology
ACC American College of Cardiology 
ACCORD Action to Control Cardiovascular Risk in Diabetes Trial.  
ACCORD-BP Action to Control Cardiovascular Risk in Diabetes- Blood Pressure
ACLS Aerobics Center Longitudinal Study 
ACR Aptitud CardiorRespiratoria
ACV Accidente CerebroVascular 
ADA American Diabetes Association
ADDITION-Cambridge Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in PrimaryCare 
ADH Alcohol DesHidrogenasa 
ADNI AntiDiabéticos No Insulínicos 
ADVANCE Action in Diabetes and Vascular Disease Study.  
ADVANCE BP Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation  Blood Pressure 
AEI Amputaciones Extremidades Inferiores
BARI-2D Bypass Angioplasty Revascularization Investigation 2 Diabetes
aGLP-1 Análogos del receptor del péptido-1 similar al glucagón
AGREE II Appraisal of Guidelines Research and Evaluation (second version)
AHA American Heart Association
AHEAD  Action for Health for Diabetes (Look AHEAD)
AHRQ Agencia para la Investigación y Calidad de la Atención Médica 
AHS-2 Adventist Health Study-2 (AHS-2), 
AI Auricula Izquierda.
AL  Acidosis Láctica
ALLHAT-LLT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial 
AMPA Automedida domiciliaria de la Presión Arterial.  
AP Atención Primaria
ARA2 Antagonistas de los Receptores de la angiotensina II
ARIC  Atherosclerosis Risk in Communities 
ARRIVE Aspirin to Reduce Risk of Initial Vascular Events
ASCEND A Study of Cardiovascular Events in Diabetes
ASCOT-LLA Anglo-Scandinavian Cardiac Outcomes Trial
ASPREE Aspirin in Reducing Events in the Elderly 
ATC Antithrombotic Trialists’ Collaboration
ATP III Adult Treatment Panel III
AUC Área bajo la Curva
BBs Betabloqueantes
CAD Cetoacidosis diabética
CANVAS Canagliflozin Cardiovascular Assessment Study
CARDIA Coronary Artery Risk Development in Young Adults
CARE Consultation And Relational Empathy
CARMELINA Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus 
CAROLINA CARdiovascular Outcomestudy of LINAgliptin versus glimepiride in patientswithtype 2 diabetes
CASCADE CArdiovaSCulAr Diabetes & Ethanol
CB Cirugía Bariátrica
CCAA Comunidades Autonomas
CCS Canadian Cardiovascular Society
CDA Canadian Diabetes Association.
CDK273 Chronic kidney disease 273
CHS Cardiovascular Health Study
BES Binge Eating Scale
CHARM Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity
CI Cardiopatia Isquémica
CK-MB creatinina cinasa, isoenzima específica del miocardio.
CM Cirugía Metabólica
CMD CardioMiopatía Diabética (CMD)
CPRD Clinical Practice Research Database 
CREDENCE Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation
CV CardioVascular
CVD-REAL Comparative  Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors
DAPA-CKD Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease
DAPA-FH Dapagliflozina y Prevención de Resultados Adversos en la Insuficiencia Cardíaca
DASH Dietary Approaches to Stop Hypertension (DASH diet).
DAWN Diabetes Attitudes, Wishes and Needs 
DAWN2 Diabetes Attitudes, Wishes and Needs 2 (segunda edición)
DCCT Diabetes Control and Complications Trial.  
D2d Vitamin D and Type 2 Diabetes
DE Desviación Estandar
DECLARE-TIMI 58 Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58
DEFINE-HF Dapagliflozin Effects on Biomarkers, Symptoms and Functional Status in Patients with HF with Reduced Ejection Fraction
DESIR Epidemiological Study on the Insulin Resistance  Syndrome
DET diferencia estimada del tratamiento 
DG Diabetes Gestacional
DiRECT Diabetes Remission Clinical Trial 
DM Diabetes Mellitus.  
DM1 Diabetes tipo 1
DM2 Diabetes Mellitus tipo 2
DPP  Diabetes Prevention Program 
DPPOS Diabetes Prevention Program Outcomes Study (DPPOS) 
DREAM Diabetes Reduction Assessment with ramipril and rosiglitazone Medication
DSM-5  Diagnostic and Statistical Manual of Mental Disorders 5
DT Diferencias de Tasas
EAG Efecto Adverso Grave
EASD European Association for the Study of Diabetes.
ECA Ensayo Clinico Aleatorizado
ECC Evento Coronario
ECG Electrocardiograma.
ECNICV Ensayos Clínicos Aleatorizados de No Inferioridad cardiovascular 
ECV Enfermedad CardioVascular
ECVa Enfermedad Cardiovascular Arteriosclerótica
EDRFA Encuestas Dietéticas Retrospectivas de Frecuencia Alimentaria
EDWPOP European Diabetes Working Party for Older People 
EGIR Grupo europeo para el estudio de la resistencia a la insulina.  
ELIXA Evaluation of  LIXisenatide in Acute Coronary Syndrome 
EMA Agencia Europea de Medicamentos
EMPA-HEART CardioLink-6 Effects of Empagliflozin on Cardiac Structure in Patients With Type 2 Diabetes  Cardiolink-6
EMPA-KIDNEY The Study of Heart and Kidney Protection With Empagliflozin
EMPA-REG OUTCOME Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose 
EMPEROR-Reduced EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction 
EMPEROR-Preserved EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction  
EMPRISE EMPagliflozin compaRative effectIveness  and SafEty
EN Emociones Negativas
EPIC European Prospective Investigation of Cancer
EPO Eritropoyetina
ER Ejercicio de Resistencia
ERC Enfermedad Renal Crónica
ERT Enfermedad Renal Terminal
erMedDiet energéticamente restrictiva de MedDiet
ESC European Society of Cardiology
ESCADIANE Estudio sobre las características de los pacientes ancianos con diabetes en España
EvCV Evento CardioVascular
EV  Estilos de Vida
EXAMINE Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care 
EXSCEL Exenatide Study of Cardiovascular Event Lowering 
FAERS FDA’s Adverse Event Reporting System 
FAH Falta de AdHerencia
FDA Food Drug Administration
FDPS Finnish Diabetes Prevention Study (FDPS)
FEVI Fracción de Eyección del Ventrículo Izquierdo
FGe Tasa de Filtración Glomerular estimada
FGm FGe media
FHS Framingham Heart Study
FIGHT Functional Impact of GLP-1 for Heart Failure Treatment 
FORCE Fatty Acids and Outcomes Research Consortium 
FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
FRCV Factor de Riesgo Cardiovascular
GB Glucosa Basal 
GBA Glucosa Basal Alterada.
GEDAPS Grupo de Estudio para la Diabetes en Atención Primaria de Salud.
GIN Guidelines International Network 
GPRD General Practice Research Database  
GTZ Glitazonas (Tiazolidinedionas)
HARMONY Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease
HbA1c Hemoglobina glicada, glucada o Glucohemoglobina.
HC Hidratos de Carbono
HDL-c colesterol ligado a lipoproteínas de alta densidad 
HFSA Heart Failure Society of American 
HGI Hemorragia GastroIntestinal
HH Hiperglucemia Hiperosmolar
HI Hiperinsulinemia.
HOPE Heart Outcomes Prevention Evaluation 
HOT Hypertension Optimal Treatment  
HR Hazard ratio
IAGG International Association of Gerontology and Geriatrics 
IAM Infarto de Miocardio 
IC Insuficiencia Cardiaca
ICE Indice cintura/estatura
ICCa Indice cintura/cadera
IC95% Intervalo de Confianza del 95%
ICFEP IC con fracción de eyección preservada
ICFER IC con fracción de eyección reducida
ICSI Institute for Clinical Systems Improvement
ICL Inercia Clínica
ICT Indice CardioTorácico.
IDF International Diabetes Federation.  
iDPP4 Inhibidores de la dipeptidilpeptidasa 4  
IECA inhibidores de la enzima conversora de la angiotensina.
IEV Intervencion en E+B31stilos de Vida
IMC Indice de masa corporal.  
IMPROVE-IT Improved Reduction of Outcomes: Vytorin Efficacy International Trial
IMVI índice de masa del VI 
InCC Indice de depósito Cálcico Coronario
INSIGHT Intervention as a Goal in Hypertension Treatment 
IPAQ-SF Physical Activity Questionnaire Short Form 
IRC Insuficiencia Renal Crónica
IRIS Insulin Resistance Intervention after Stroke
IRR incidence rate ratio (IRR)
iSGLT2 Inhibidores del cotransportador de sodio-glucosa 2 
IT Inercia Terapéutica
ITG Intolerancia a la glucosa
IWGDF International Working Group on the Diabetic Foot 
JUPITER Justification for the Use of statins in Prevention: an Intervention Trial Evaluating rosuvastatin
K+ Potasio
KDIGO Kidney Disease: Improving Global Outcomes 
KPNC Kaiser Permanente Northern California 
LDL-col Lipoproteina de baja densidad-colesterol
LEADER Liraglutide Effect and Action in Diabetes: Evaluation of  cardiovascular Outcome Results 
LINA Linagliptina
LTC Centros de Atención a largo plazo 
MACE Major Adverse Cardiovascular Events (eventos adversos cardiovasculares mayores)
MAPA Monitorización Ambulatoria de la Presión Arterial.
MBE Metodología Basada en la Evidencia  o Medicina Basada en la Evidencia
MCC Muerte por Cualquier Causa
MCP-1 proteína quimiotáctica de monocitos tipo 1
MCV Muerte de causa CardioVascular
MD Mediana de Diferencia de medias
MEASURE-HF Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure
MedDiet Dieta Mediterránea
MesH Medical Subject Headings
MET Metformina
MEV Modificación en los Estilos de Vida
MFR Multiples Factores de Riesgo
MNA Mini Nutritional Assessment
MODY Maturity-Onset Diabetes of the Young 
MUFA Mono- Unsaturated Fatty Acids
MUST Malnutrition Universal Screening Tool
Na Sodio
NCEP US National Cholesterol Education Programme.  
NDM Nefropatia Diabética
NDEP National Diabetes Education Program 
NGC National Guidelines Clearinghouse 
NGSP National Glycohemoglobin Standardization Program.  
NHANES National Health and Nutrition Examination Survey 
NHMRC Australian Government National Health and Medical Research Council
NICE National Institute for Clinical Excellence.  
NIS Nationwide Inpatient Sample 
NMA Network-Meta Analysis 
NNH Número necesario a tratar para producir un evento adverso
NNT Número Necesario a Tratar
NNT10 NNT en 10 años
NT-proBNP  fracción N terminal de la prohormona del peptido natriurético cerebral 
NYHA New York Heart Association
ODYSSEY OUTCOMES Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
OMS Organización Mundial de la Salud
ON Óxido Nítrico
OECD Organisation for Economic Co-operation and Development 
PA Presión Arterial
PAD Presión Arterial Diastólica
PAS Presión Arterial Sistólica
PC  Perímetro de Cintura
PCDE Primary Care Diabetes Eurrope
PCSK9 Proprotein Convertasa Subtilisin Kexin 9
PDA Polish Diabetes Association
PDC Proporción de Días Cubiertos
PERCEDIME Prevalencia de la Enfermedad Renal  Crónica En pacientes con DIabetes MEllitus  tipo 2 en las consultas de atención primaria
PIO Pioglitazona
PIONEER Peptide InnOvatioN for Early DiabEtes TReatment 
PP Prevencion Primaria
PRED PREDiabetes  
PREDAPS PREDiabetes en Atención Primaria de Salud (Primary Health Care on the Evolution of Patients with Prediabetes )
PREDIMED PREvención con DIeta MEDiterránea
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses
PROactive PROspective pioglitAzone Clinical Trial In macroVascular Events  
PROSPER Pravastatin in elderly individuals at risk of vascular disease 
PRR tasa proporcionales por año
PTH Paratohormona
PUFA Poly- Unsaturated Fatty Acids
PRIORITY Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria
QALYs años de vida ajustados por calidad neta (QALYs) 
RAMQ Régie de l’assurance maladie du Québec 
RCV Riesgo CardioVascular
RECORD Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes
REGICOR Registre Gironí del Cor
REWIND Researching cardiovascular Events with a Weekly INcretin in Diabetes
RI Resistencia a la insulina.
RIGHT Reporting Items for Practice Guidelines in Healthcare
RMN Resonancia Magnética Nuclear
RMNC Resonancia Magnética Nuclear Cardíaca 
RNAO Registered Nurses' Association of Ontario
ROSE The Retrospective Study of Cardiovascular Events Related to the Use of Glucose-Lowering Drug Treatment in Primary Care 
RTDM Retinopatia Diabética
RTDML Retinopatia Diabética Leve
SAVOR-TIMI Saxagliptin Assessment of Vascular Outcomes Recorded in Patients With Diabetes Mellitus–Thrombolysis in Myocardial Infarction 
SCORED Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk 
SEARCH SEARCH for Diabetes in Youth (SEARCH) 
SIDIAP Spanish Information System for the Development of Research in Primary Care 
SIGN Scottish Intercollegiate Guidelines Network 
SMC Standars of Medical Care
SMS Servicio de Mensajes Simples 
SNP nucleótidos de un solo polimorfismo 
SOG Prueba de tolerancia oral a la glucosa.  
SOP Síndrome de Ovario Poliquistico
SOS Swedish Obese Subjects  
SPRINT Systolic Blood Pressure Intervention Trial
STAMPEDE  Surgical Therapy and Medications Potentially Eradicate Diabetes Efficiently
STAREE Statins for Reducing Events in the Elderly 
STENO 2 Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.  
SURDIAGENE  Suivi Rénal, DIAbète de type 2 et GENEtique
SUSTAIN Semaglutide in Subjects with Type 2 Diabetes 
TECOS Trial Evaluating Cardiovascular Outcomes with Sitagliptin 
THEMIS Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study
THIN The Health Improvement Network 
TOSCA IT Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial 
UCI Unidad de Cuidados Intensivos.
UD Úlcera diabética
UKPDS United Kingdom Prospective Diabetes Study Group.
USPSTF US Preventive Services Task Force 
VA Veterans Affairs
VADT Veterans Affairs Diabetes Trial
VD Ventrículo derecho.
VEGF Vascular Endothelial Growth Factor  
VERIFY Vildagliptin Efficacy in combination with metfoRmIn For earlY treatment of type 2 diabetes
VERTIS CV eValuation of ERTugliflozin effIcacy and Safety CardioVascular 
VI Ventrículo izquierdo.
VIVIDD Vildagliptin in Ventricular Dysfunction Diabetes
WHI Women’s Health Initiative
WHS Wound Healing Society

No hay comentarios: